Marburg (Experimental)
Marburg Virus — Experimental Vaccine Candidates
Platform: Pathogen — No Licensed Vaccine
Highly lethal filovirus causing Marburg hemorrhagic fever — vaccine candidates are in early clinical trials with no licensed product.
EXPERIMENTAL — No licensed vaccine or therapeutic currently approved.
Immunology Sections
Curated section analysis in progress
Structured immunology sections — mechanism, immune response, molecular signatures, correlates of protection, and more — are being prepared by the Precision Vaccines Program team. In the meantime, verified references and live literature from PubMed, Semantic Scholar, and Wikipedia are available below.
Wikipedia Overview
Full article ↗
Marburg virus (MARV) is a hemorrhagic fever virus of the Filoviridae family of viruses and a member of the species Marburg marburgvirus, genus Marburgvirus. It causes Marburg virus disease in primates, a form of viral hemorrhagic fever. The World Health Organization (WHO) rates it as a Risk Group 4 Pathogen. In the United States, the National Institute of Allergy and Infectious Diseases ranks it as a Category A Priority Pathogen and the Centers for Disease Control and Prevention lists it as a Category A Bioterrorism Agent. It is also listed as a biological agent for export control by the Australia Group.
PubMed Literature
Search PubMed ↗No PubMed results retrieved.
Semantic Scholar
Search S2 ↗No Semantic Scholar results retrieved.